Climb Bio (CLYM) Notes Payables (2020 - 2022)

Climb Bio (CLYM) posted Notes Payables of $21000.0 for Q2 2022, down 89.86% on a QoQ basis from $207000.0 in Q4 2020.

Climb Bio (CLYM) Notes Payables (2020 - 2022) Analysis & Trends

Climb Bio's Notes Payables history runs 2 years deep, the most recent figure standing at $21000.0 for Q2 2022.

Quarterly Notes Payables changed N/A year-over-year to $21000.0 in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $21000.0 (changed N/A YoY) and the FY2020 annual result came in at $207000.0, changed N/A from the prior year.
Notes Payables was $21000.0 for Q2 2022 at Climb Bio, down from $207000.0 in the prior quarter.
Across five years, Notes Payables topped out at $207000.0 in Q4 2020 and bottomed at $21000.0 in Q2 2022.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Climb Bio	870.33 Mn	870.33 Mn	-

Historic Data

Download Data

Date	Value
Jun 30, 2022	21,000.00
Dec 31, 2020	207,000.00